MEDX getting noticed:
The Wall Street Transcript Publishes Special Pharmaceutical Industry
Issue
NEW YORK, Jan. 24 /PRNewswire/ -- Six leading analysts and top management from six firms examine the
pharmaceutical
sector in the latest issue of The Wall Street Transcript (212-952-7433) or twst.com.
In a vital review of this sector for investors and industry professionals, this valuable 63-page report features:
The Wall Street Transcript Publishes Special Pharmaceutical Industry Issue
NEW YORK, Jan. 24 /PRNewswire/ -- Six leading analysts and top management from six firms examine the
pharmaceutical
sector in the latest issue of The Wall Street Transcript (212-952-7433) or twst.com.
In a vital review of this sector for investors and industry professionals, this valuable 63-page report features:
Traversa believes, "Monoclonal antibodies have been promising for more than 20 years. However it is only in
1998 and 1999 that we have seen the real market potential of this class of products with the successful
launches of MedImmune's (Nasdaq: MEDI) Synagis for respiratory syncytial virus (RSV) infections,
Genentech's (NYSE: DNA) Herceptin for breast cancer, and Genentech/IDEC/Roche's Rituxan for
non-Hodgkin's lymphoma (NHL). I believe that the role of this class of drugs will gradually increase moving
forward and monoclonal antibodies will become an integrating part of the drug portfolio of pharmaceutical
companies and doctors."
Traversa adds, "The next program currently in development is the creation of fully human monoclonal
antibodies, which should eliminate almost entirely the immunogenicity issue. Human antibodies could then be
used in large patient population and importantly, should be used for the treatment of chronic diseases,
expanding severalfold their market potential. The two biotech companies that are leading this effort are Abgenix
(Nasdaq: ABGX - news) and Medarex (Nasdaq: MEDX - news).' ...... |
